USDOJ 2017 UPDATE OF THE ANTITRUST GUIDELINES FOR THE LICENSING OF INTELLECTUAL PROPERTY STANDARD SETTING AND COMPETITION November 8, 2012 COMPETITION, INNOVATION AND INTELLECTUAL PROPERTY, April 26, 2012 CHAPTER 6 : COMPETITIVE ISSUES REGARDING PRACTICES THAT EXTEND THE MARKET POWER… Continue Reading
(More on compulsory licensing here.) This is a non-exhaustive set of provisions in US statutes that are used to for non-voluntary use of patented inventions. 28 USC 1498 – Patent and copyright cases 28 USC 1498(a). http://www.gpo.gov/fdsys/granule/USCODE-2011-title28/USCODE-2011-title28-partIV-chap91-sec1498/content-detail.html 42 USC Sec… Continue Reading
(More on government funded inventions here.) On January 14, 2016, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted a request to the National Institutes of Health (NIH) and Department of Defense (DoD) asking that they… Continue Reading
On August 13, 2014, the Republic of South Africa (RSA) Competition Commission (CC) released the redacted versions of the reports provided to the CC by CPTech in 2003 in the TAC competition case involving GSK and Boehringer Ingelheim. A complete… Continue Reading
July 15, 2014
Knowledge Ecology International (KEI) asks the FTC to investigate Shire decision to abandon efforts to compete in US market for Fabry’s disease treatments. Letter to FTC provides evidence of possible conspiracy to segment markets, involving licensing of an NIH funded invention for use in Europe, in return for abandoning efforts to enter US market.
For More Information:
James Love, Knowledge Ecology International
Informed sources have revealed that Mark Dybul, Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, is the brains behind an initiative to create global framework for the tiered pricing or in the Global Fund’s own words, “Equitable Access to Essential Medicines and Vaccines: Developing a Framework for Success”, enforced by the rules of the World Trade Organization. KEI has obtained this internal concept note prepared by the Global Fund which we understand is a work in progress.
John L. LaMattina, the former President of Pfizer Global Research and Development, has just published an article in Nature that looks at the impact of drug company mergers and increased industry concentration on R&D. Among his conclusions: the “impact on the R&D of the organizations involved has been devastating.”
NATURE REVIEWS | DRUG DISCOVERY VOLUME 10 | AUGUST 2011 | 559
The impact of mergers on pharmaceutical R&D
On the 24th of November, 59 U.S. Senators wrote the European Union, asking that the Oracle/Sun merger be allowed, without addressing the anticompetitive aspects of the Oracle acquisition of MySQL. The letter reflects the enormous influence wielded by Oracle, a company that generates enormous fees licensing database software to the federal government. Continue Reading
KEI, Richard Stallman, ORG, letter to European Commission opposing Oracle acquisition of MySQL assets from Sun The following is a letter that KEI, Richard Stallman and ORG have sent to the European Commission, asking the European Commission to prevent Oracle… Continue Reading